Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03580694
Title Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Regeneron Pharmaceuticals

lung non-small cell carcinoma


Cemiplimab + REGN4659


Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST